Picture of Vitrolife AB logo

VITR — Vitrolife AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Sweden's Vitrolife Q3 revenue rises on technology segment growth

Sweden's Vitrolife Q3 revenue rises on technology segment growth


Overview

  • Sweden medical devices and genetic testing firm's Q3 revenue rose 6% in SEK

  • Net income and EBITDA increased yr/yr, with Q3 net income at SEK 124 mln

  • Company repurchased SEK 246 mln of shares under SEK 500 mln buyback program


Outlook

  • Vitrolife did not provide specific guidance for future quarters or the full year in the press release


Result Drivers

  • TECHNOLOGIES SALES - Q3 sales in Technologies product group grew 21%, supporting overall revenue growth

  • EMEA REGION - EMEA sales rose 11% in Q3, outpacing growth in other regions

  • GROSS MARGIN IMPROVEMENT - Gross margin increased to 59.2% from 58.9% in Q3


Company press release: ID:nMFN2knhMn


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

SEK 884 mln

Q3 Net Income

SEK 124 mln

Q3 EBITDA

SEK 279 mln

Q3 EBITDA Margin

31.60%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Vitrolife AB is SEK135.00, about 38% above its October 21 closing price of SEK97.80

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 23 three months ago


Reuters Recommended Reads

  • Oct 22 - Sweden's Arjo Q3 revenue beats estimates, gross margin expands

  • Oct 22 - Sweden's XVIVO Q3 revenue beat expectations on thoracic sales

  • Oct 21 - Sweden's AddLife beats Q3 net sales expectations


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Vitrolife AB

See all news